Use of a Commercially Available Clinical Decision Support Tool to Expedite Prior Authorization in Partnership With a Private Payer.

Autor: Gaskin CM; Vice Chair of Clinical Operations and Informatics, Division Chief of Musculoskeletal Imaging and Intervention, and Associate Chief Medical Information Officer, Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia. Electronic address: cree@virginia.edu., Ellenbogen AL; Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia., Parkhurst KL; Business Office Manager, Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia., Matsumoto AH; Chair of the Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia.

Publikováno v: Journal of the American College of Radiology : JACR [J Am Coll Radiol] 2021 Jun; Vol. 18 (6), pp. 857-863. Date of Electronic Publication: 2021 Jan 29.

Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.

Autor: Falchook GS; Sarah Cannon Research Institute, 1800 Williams Street, Suite 300, Denver, CO, 80218, USA. gerald.falchook@scresearch.net., Rady P; Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX, USA., Konopinski JC; Baylor College of Medicine, Houston, TX, USA., Busaidy N; Division of Internal Medicine, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Hess K; Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Hymes S; Division of Internal Medicine, Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Nguyen HP; Baylor College of Medicine, Houston, TX, USA., Prieto VG; Division of Pathology and Laboratory Medicine, Departments of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Bustinza-Linares E; Florida Cancer Specialists, Orlando, FL, USA., Lin Q; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Parkhurst KL; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Hong DS; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Sherman S; Division of Internal Medicine, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA., Tyring SK; Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX, USA., Kurzrock R; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.

Publikováno v: Archives of dermatological research [Arch Dermatol Res] 2016 Jul; Vol. 308 (5), pp. 357-65. Date of Electronic Publication: 2016 Apr 20.

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.

Autor: Falchook GS; Sarah Cannon Research Institute, Denver, CO 80218., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Naing A; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Jackson EF; Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705., Janku F; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Hong D; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Ng CS; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Lawhorn KN; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Huang M; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Angelo LS; Department of Immunology, Allergy, and Rheumatology, The Center for Human Immunobiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX 77030., Vishwamitra D; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Hess K; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Howard AN; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Parkhurst KL; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Amin HM; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030., Kurzrock R; Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, San Diego, CA 92093.

Publikováno v: Oncotarget [Oncotarget] 2014 Nov 15; Vol. 5 (21), pp. 10280-92.

Contribution of blood viscosity in the assessment of flow-mediated dilation and arterial stiffness.

Autor: Parkhurst KL; Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA., Lin HF, Devan AE, Barnes JN, Tarumi T, Tanaka H

Publikováno v: Vascular medicine (London, England) [Vasc Med] 2012 Aug; Vol. 17 (4), pp. 231-4.